Life Technologies Forms Team to Focus on IP Licensing for PCR, other Products

The revamped licensing effort has been able to slow a drop-off in royalty revenues from Life Tech's PCR patent estate that had previously been predicted to decline by $30 million in 2009 but has so far only declined by $20 million.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.